Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2022

09-01-2022 | Ulcerative Colitis | Original Article

Fecal Microbiota Transplant for Clostridioides Difficile Infection Is Safe and Efficacious in an Immunocompromised Cohort

Authors: Kelly Suchman, Yuying Luo, Ari Grinspan

Published in: Digestive Diseases and Sciences | Issue 10/2022

Login to get access

Abstract

Background

Immunocompromised patients are particularly vulnerable to Clostridioides difficile infection (CDI), hospitalizations and recurrences. Studies have shown that fecal microbiota transplant (FMT) is safe and effective in immunocompromised patients.

Aims

To examine the outcomes of FMT for CDI in a diverse cohort of immunocompromised patients stratified by medication class.

Methods

We performed a retrospective, long-term follow-up study of FMT in immunocompromised patients, including those undergoing chemotherapy, with inflammatory bowel disease (IBD) on immunomodulators, prior solid organ transplant on immunosuppressants, on chronic steroids 20 mg/day or higher for a minimum of three months, or HIV positive. Primary outcomes included adjusted primary cure rate within 8 weeks, as well as rates of non-response, recurrences, relapses and adverse events. Secondary outcomes included adjusted overall cure rate. Primary cure rate was defined as patients not requiring repeat CDI treatment within 8 weeks after index FMT, and overall cure rate was defined as resolution of CDI symptoms after index FMT or second FMT.

Results

Our cohort included 77 immunosuppressed patients (53.2% female, median age 39.1 years, range 7–95 years). The majority of our cohort were IBD patients on biologics (62.3%). Adjusting for colectomies and deaths, our primary and overall cure rates were 85.1% and 86.5%, respectively. Twelve patients received FMT for severe or fulminant CDI with a 3-month survival rate of 91.7%. 11.7% of patients experienced serious adverse events following FMT.

Conclusions

Our study supports the efficacy and safety of FMT in immunocompromised patients, though future research is needed to further ascertain the potential effects of immunosuppression on FMT outcomes.
Literature
1.
go back to reference Lessa FC, Mu Y, Bamberg WM et al. Burden of Clostridium Dificile infection in the United States. N Engl J Med 2015;372:825–834.CrossRef Lessa FC, Mu Y, Bamberg WM et al. Burden of Clostridium Dificile infection in the United States. N Engl J Med 2015;372:825–834.CrossRef
2.
go back to reference King RN, Lager SL. Incidence of Clostridium difficile Infections in Patients Receiving Antimicrobial and Acid-Suppression Therapy. Pharmacotherapy 2011;31:642–648.CrossRef King RN, Lager SL. Incidence of Clostridium difficile Infections in Patients Receiving Antimicrobial and Acid-Suppression Therapy. Pharmacotherapy 2011;31:642–648.CrossRef
3.
go back to reference Kelly CP, LaMont JT. Clostridium difficile—more difficult than ever. N Engl J Med 2008;359:1932–1940.CrossRef Kelly CP, LaMont JT. Clostridium difficile—more difficult than ever. N Engl J Med 2008;359:1932–1940.CrossRef
4.
go back to reference McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;97:1769–1775.CrossRef McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;97:1769–1775.CrossRef
5.
go back to reference Van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407–415.CrossRef Van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407–415.CrossRef
6.
go back to reference Cammarota G, Masucci L, Ianiro G et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015;41:835–843.CrossRef Cammarota G, Masucci L, Ianiro G et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015;41:835–843.CrossRef
7.
go back to reference McDonald LC, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:e1–e48.CrossRef McDonald LC, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:e1–e48.CrossRef
8.
go back to reference Abu-Sbeih H, Ali FS, Wang Y. Clinical review on the utility of fecal microbiota transplantation in immunocompromised patients. Curr Gastroenterol Rep 2019;21:8.CrossRef Abu-Sbeih H, Ali FS, Wang Y. Clinical review on the utility of fecal microbiota transplantation in immunocompromised patients. Curr Gastroenterol Rep 2019;21:8.CrossRef
9.
go back to reference Cózar-Llistó A, Ramos-Martinez A, Cobo J. Clostridium difficile infection in special high-risk populations. Infect Dis Ther 2016;5:253–269.CrossRef Cózar-Llistó A, Ramos-Martinez A, Cobo J. Clostridium difficile infection in special high-risk populations. Infect Dis Ther 2016;5:253–269.CrossRef
10.
go back to reference Kamboj M, Son C, Cantu S et al. Hospital-onset Clostridium difficile infection rates in persons with cancer or hematopoietic stem cell transplant: a C3IC network report. Infect Control Hosp Epidemiol 2012;33:1162–1165.CrossRef Kamboj M, Son C, Cantu S et al. Hospital-onset Clostridium difficile infection rates in persons with cancer or hematopoietic stem cell transplant: a C3IC network report. Infect Control Hosp Epidemiol 2012;33:1162–1165.CrossRef
11.
go back to reference Bakken JS, Borody T, Brandt LJ et al. Treating Clostridium difficile infection with fecal microbiota transplantation. J Clin Gastroenterol Hepatol 2011;9:1044–1049.CrossRef Bakken JS, Borody T, Brandt LJ et al. Treating Clostridium difficile infection with fecal microbiota transplantation. J Clin Gastroenterol Hepatol 2011;9:1044–1049.CrossRef
12.
go back to reference DeFilipp Z, Bloom PP, Torres Soto M et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med 2019;381:2043–2050.CrossRef DeFilipp Z, Bloom PP, Torres Soto M et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med 2019;381:2043–2050.CrossRef
13.
go back to reference Cheng YW, Phelps E, Ganapini V et al. Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience. Am J Transplant 2019;19:501–511.CrossRef Cheng YW, Phelps E, Ganapini V et al. Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience. Am J Transplant 2019;19:501–511.CrossRef
14.
go back to reference Kelly CR, Ihunnah C, Fischer M et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014;109:1065–1071.CrossRef Kelly CR, Ihunnah C, Fischer M et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014;109:1065–1071.CrossRef
15.
go back to reference Shogbesan O, Poudel DR, Victor S et al. A systematic review of the efficacy and safety of fecal microbiota transplant for Clostridium difficile infection in immunocompromised patients. Can J Gastroenterol Hepatol 2018;2018:1394379.CrossRef Shogbesan O, Poudel DR, Victor S et al. A systematic review of the efficacy and safety of fecal microbiota transplant for Clostridium difficile infection in immunocompromised patients. Can J Gastroenterol Hepatol 2018;2018:1394379.CrossRef
16.
go back to reference Bakken JS, Borody T, Brandt LJ et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011;9:1044–1049.CrossRef Bakken JS, Borody T, Brandt LJ et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011;9:1044–1049.CrossRef
17.
go back to reference Allegretti JR, Allegretti AS, Phelps E et al. Classifying Fecal Microbiota Transplantation Failure: An Observational Study Examining Timing and Characteristics of Fecal Microbiota Transplantation Failures. J Clin Gastroenterol Hepatol. 2017;16:1832–1833.CrossRef Allegretti JR, Allegretti AS, Phelps E et al. Classifying Fecal Microbiota Transplantation Failure: An Observational Study Examining Timing and Characteristics of Fecal Microbiota Transplantation Failures. J Clin Gastroenterol Hepatol. 2017;16:1832–1833.CrossRef
18.
go back to reference Surawicz CM, Brandt LJ, Binion DG et al. Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections. Am J Gastroenterol 2013;108:478–498.CrossRef Surawicz CM, Brandt LJ, Binion DG et al. Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections. Am J Gastroenterol 2013;108:478–498.CrossRef
21.
go back to reference Nicholson MR, Mitchell PD, Alexander E et al. Efficacy of fecal microbiota transplantation for Clostridium difficile infection in children. J Clin Gastroenterol Hepatol. 2020;18:e612-619.CrossRef Nicholson MR, Mitchell PD, Alexander E et al. Efficacy of fecal microbiota transplantation for Clostridium difficile infection in children. J Clin Gastroenterol Hepatol. 2020;18:e612-619.CrossRef
22.
go back to reference Chen T, Zhou Q, Zhang D et al. Effect of faecal microbiota transplantation for treatment of Clostridium difficile infection in patients with inflammatory bowel disease: a systematic review and meta-analysis of cohort studies. J Crohns Colitis 2018;12:710–717.CrossRef Chen T, Zhou Q, Zhang D et al. Effect of faecal microbiota transplantation for treatment of Clostridium difficile infection in patients with inflammatory bowel disease: a systematic review and meta-analysis of cohort studies. J Crohns Colitis 2018;12:710–717.CrossRef
23.
go back to reference Allegretti JR, Kelly CR, Grinspan A et al. Outcomes of fecal microbiota transplantation in patients with inflammatory bowel diseases and recurrent Clostridioides difficile infection. Gastroenterology 2020;159:1982–1984.CrossRef Allegretti JR, Kelly CR, Grinspan A et al. Outcomes of fecal microbiota transplantation in patients with inflammatory bowel diseases and recurrent Clostridioides difficile infection. Gastroenterology 2020;159:1982–1984.CrossRef
24.
go back to reference Fischer M, Kao D, Kelly C et al. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2016;22:2402–2409.CrossRef Fischer M, Kao D, Kelly C et al. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2016;22:2402–2409.CrossRef
25.
go back to reference Allegretti JR, Kelly CR, Grinspan A, et al. Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection. Inflamm Bowel Dis 2020;izaa283 Allegretti JR, Kelly CR, Grinspan A, et al. Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection. Inflamm Bowel Dis 2020;izaa283
26.
go back to reference Moayyedi P, Surette MG, Kim PT et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015;149:102–109.CrossRef Moayyedi P, Surette MG, Kim PT et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015;149:102–109.CrossRef
27.
go back to reference Rossen NG, Fuentes S, van der Spek MJ et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 2015;149:110–118.CrossRef Rossen NG, Fuentes S, van der Spek MJ et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 2015;149:110–118.CrossRef
28.
go back to reference Paramsothy S, Kamm MA, Kaakoush NO et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. The Lancet 2017;389:1218–1228.CrossRef Paramsothy S, Kamm MA, Kaakoush NO et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. The Lancet 2017;389:1218–1228.CrossRef
29.
go back to reference Costello SP, Hughes PA, Waters O et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. Jama 2019;321:156–164.CrossRef Costello SP, Hughes PA, Waters O et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. Jama 2019;321:156–164.CrossRef
30.
go back to reference McDonald LC, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases 2018;66:e1–e48.CrossRef McDonald LC, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases 2018;66:e1–e48.CrossRef
31.
go back to reference Kelly CR, Fischer M, Allegretti JR et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Official J Am College Gastroenterol 2021;116:1124–1147.CrossRef Kelly CR, Fischer M, Allegretti JR et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Official J Am College Gastroenterol 2021;116:1124–1147.CrossRef
32.
go back to reference Cheng YW, Phelps E, Nemes S et al. Fecal microbiota transplant decreases mortality in patients with refractory severe or fulminant Clostridioides difficile infection. Clin Gastroenterol Hepatol 2020;18:2234–2243.CrossRef Cheng YW, Phelps E, Nemes S et al. Fecal microbiota transplant decreases mortality in patients with refractory severe or fulminant Clostridioides difficile infection. Clin Gastroenterol Hepatol 2020;18:2234–2243.CrossRef
33.
go back to reference Tixier EN, Verheyen E, Ungaro RC, Grinspan AM. Faecal microbiota transplant decreases mortality in severe and fulminant Clostridioides difficile infection in critically ill patients. Aliment Pharmacol Ther 2019;50:1094–1099.CrossRef Tixier EN, Verheyen E, Ungaro RC, Grinspan AM. Faecal microbiota transplant decreases mortality in severe and fulminant Clostridioides difficile infection in critically ill patients. Aliment Pharmacol Ther 2019;50:1094–1099.CrossRef
34.
go back to reference Fischer M, Sipe B, Cheng Y et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes 2017;8:289–302.CrossRef Fischer M, Sipe B, Cheng Y et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes 2017;8:289–302.CrossRef
35.
go back to reference Sailhamer EA, Carson K, Chang Y et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg 2009;144:433–439.CrossRef Sailhamer EA, Carson K, Chang Y et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg 2009;144:433–439.CrossRef
36.
go back to reference Dallal RM, Harbrecht BG, Boujoukas AJ et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002;235:363.CrossRef Dallal RM, Harbrecht BG, Boujoukas AJ et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002;235:363.CrossRef
37.
go back to reference Dudukgian H, Sie E, Gonzalez-Ruiz C, Etzioni DA, Kaiser AMC. difficile colitis—predictors of fatal outcome. J Gastrointest Surg 2010;14:315–322.CrossRef Dudukgian H, Sie E, Gonzalez-Ruiz C, Etzioni DA, Kaiser AMC. difficile colitis—predictors of fatal outcome. J Gastrointest Surg 2010;14:315–322.CrossRef
38.
go back to reference Kelly CR, Yen EF, Grinspan AM et al. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology 2020;160:183–192.CrossRef Kelly CR, Yen EF, Grinspan AM et al. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology 2020;160:183–192.CrossRef
Metadata
Title
Fecal Microbiota Transplant for Clostridioides Difficile Infection Is Safe and Efficacious in an Immunocompromised Cohort
Authors
Kelly Suchman
Yuying Luo
Ari Grinspan
Publication date
09-01-2022
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-07347-x

Other articles of this Issue 10/2022

Digestive Diseases and Sciences 10/2022 Go to the issue